Marshall Wace North America’s Emergent Biosolutions EBS Stock Holding History

Marshall Wace North America’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1.07M	Buy	+21,341	New	+$1.29M	﹤0.01%	896
2019 Q4	–	Sell	-12,573	Closed	-$657K	–	1354
2019 Q3	$657K	Sell	12,573 -34,842	-73%	-$1.62M	﹤0.01%	764
2019 Q2	$2.29M	Buy	47,415 +42,715	+909%	+$2.05M	0.01%	534
2019 Q1	$237K	Buy	4,700 +3,359	+250%	+$198K	﹤0.01%	948
2018 Q4	$79K	Buy	+1,341	New	+$86.4K	﹤0.01%	1134
2018 Q1	–	Sell	-117,293	Closed	-$5.45M	–	1493
2017 Q4	$5.45M	Buy	+117,293	New	+$4.94M	0.03%	560

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return

Marshall Wace North America's EBS Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Emergent Biosolutions (EBS) in Q3 2021: 21,341 shares worth $1.07M. The stake represents ﹤0.01% of the portfolio and ranks #896 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in EBS as recently as Q3 2019.

Marshall Wace North America first reported a position in EBS in Q4 2017 and has held it in 6 quarters since. The position peaked at $5.45M in Q4 2017. 277 funds tracked by Wall St. Rank hold EBS as of Q3 2021.

Marshall Wace North America held 21,341 shares of Emergent Biosolutions worth $1.07M as of Q3 2021.
Emergent Biosolutions was a new Marshall Wace North America position in Q3 2021.
Emergent Biosolutions made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #896 holding.
Marshall Wace North America first reported a position in Emergent Biosolutions in Q4 2017 and has held it in 6 quarters since.
Marshall Wace North America's Emergent Biosolutions position peaked at $5.45M in Q4 2017.
277 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.